Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 9,813 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Advanced Clear all

Conditions: Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma, Biliary Tract Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer
Interventions: BL-M07D1; Drug
Lead sponsor: SystImmune Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 26
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 19 more

Conditions: Advanced Solid Malignancies
Interventions: CT7001, Fulvestrant; Drug
Lead sponsor: Carrick Therapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 12
States / cities: Tucson, Arizona • Beverly Hills, California • Tampa, Florida + 9 more

Conditions: Neoplasm Metastases, Hepatic Insufficiency
Interventions: Trabectedin, Dexamethasone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 6
States / cities: Scottsdale, Arizona • Detroit, Michigan • New York, New York + 3 more

Conditions: Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Interventions: PF-08046045; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 15
States / cities: Palo Alto, California • Coral Gables, Florida • Miami, Florida + 10 more

Conditions: Pancreas Cancer
Interventions: Pembrolizumab, Azacitidine; Drug
Lead sponsor: Susan E. Bates; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma (Skin)
Interventions: Cisplatin, dacarbazine, Granulocyte-macrophage colony-stimulating factor; Drug
Lead sponsor: University of Chicago; Other
Eligibility: Not listed
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Malignant Hepatobiliary Neoplasm
Interventions: Laboratory Biomarker Analysis, Ponatinib Hydrochloride, Quality-of-Life Assessment; Other · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Lung Cancer
Interventions: Temozolomide; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Waukesha, Wisconsin

Conditions: Metastatic Colorectal Cancer
Interventions: Cetuximab, BAY 43-9006; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma (Skin)
Interventions: oblimersen sodium, dacarbazine; Biological · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Adult Primary Liver Cancer, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
Interventions: TSR-022 and TSR-042; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Honolulu, Hawaii • Portland, Oregon

Conditions: Cancer
Interventions: Not listed
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: Not listed
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 3
States / cities: Fort Lauderdale, Florida • Columbus, Ohio • Nashville, Tennessee

Conditions: Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Interventions: JDQ443; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Sarcoma
Interventions: temsirolimus plus liposomal doxorubicin; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 1 Year and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cancer, Pain, Advanced Cancer
Interventions: Cancer Pain 101; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: alvespimycin hydrochloride; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Lung Cancer
Interventions: Ganetespib (STA-9090) and crizotinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Metastatic Breast Cancer
Interventions: Atezolizumab, Trastuzumab emtansine, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 15
States / cities: Orange, California • Aurora, Colorado • Washington D.C., District of Columbia + 12 more

Conditions: Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Veliparib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 9
States / cities: Chicago, Illinois • Harvey, Illinois • Ann Arbor, Michigan + 6 more

Conditions: Advanced Solid Tumors
Interventions: PUR001; Drug
Lead sponsor: Purinomia Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Breast Neoplasms
Interventions: Disitamab vedotin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 120
States / cities: Daphne, Alabama • Foley, Alabama • Mobile, Alabama + 96 more

Conditions: Pancreatic Cancer
Interventions: Rexin-G Dose 1, Rexin-G Dose 2, Rexin-G Dose 3, Rexin-G Dose 4; Genetic
Lead sponsor: Epeius Biotechnologies; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Stage IVA Pancreatic Cancer, Stage III Pancreatic Cancer, Adenocarcinoma of the Pancreas
Interventions: fluorouracil, gemcitabine; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Timeline: 2000 – 2002
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Cancer, Cancer (Solid Tumors)
Interventions: JMT108; Drug
Lead sponsor: Conjupro Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Huntersville, North Carolina • Dallas, Texas • Fairfax, Virginia

Search by objective public record fields.

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers

Azacitidine and Pembrolizumab in Pancreatic Cancer

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma

Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

Temozolomide in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer

Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301

TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer

Met Non Small Cell Cancer Registry (MOMENT)

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma

Cancer Pain 101: A Digital, Asynchronous Intervention of Pain Management in Advanced Cancer

17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma

Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer

Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas

A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors